Cellectis (CLLS) Free Cash Flow (2015 - 2026)
Cellectis (CLLS) posted quarterly Free Cash Flow of -$15.1 million for Q1 2026, up 9.66% year-over-year from -$13.8 million in Q1 2025, and down 3.73% quarter-over-quarter from -$14.6 million in Q4 2025.
Powered by 
Analysis
Cellectis (CLLS) Free Cash Flow (2015 - 2026) Analysis & Trends
Cellectis' Free Cash Flow history runs 12 years deep, the most recent figure standing at -$15.1 million for Q1 2026.
- In Q1 2026, Free Cash Flow rose 9.66% year-over-year to -$15.1 million; the TTM figure through Mar 2026 stood at -$40.1 million (down 250.13% YoY), while the FY2025 annual figure was -$41.8 million, down 304.65% from the prior year.
- Free Cash Flow for Q1 2026 stood at -$15.1 million, down from -$14.6 million in the prior quarter.
- The five-year high for Free Cash Flow was $53.2 million in Q2 2024, with the low at -$36.0 million in Q1 2022.
- The 5-year median for Free Cash Flow is -$15.1 million (2026), against an average of -$9.0 million.
- The sharpest annual moves came in 2022 and 2023: Free Cash Flow slumped 239.39% in 2022, then surged 771.05% in 2023.
- Cellectis' Free Cash Flow stood at -$5.6 million in 2022, then soared by 771.05% to $37.8 million in 2023, then tumbled by 112.32% to -$4.7 million in 2024, then tumbled by 213.12% to -$14.6 million in 2025, then dropped by 3.73% to -$15.1 million in 2026.
- Business Quant data shows CLLS's Free Cash Flow at -$15.1 million in Q1 2026, -$14.6 million in Q4 2025, and -$390000.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -563.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -389.61 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 437.80 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 292.04 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 477.44 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -95.09 Mn |
| 10 | Cellectis | 321.90 Mn | 155.05 Mn | - | -14.03 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -14.03 Mn |
| Mar 31, 2026 | -15.15 Mn |
| Dec 31, 2025 | -9.88 Mn |
| Sep 30, 2025 | -390,000.00 |
| Jun 30, 2025 | -10.01 Mn |
| Mar 31, 2025 | -16.77 Mn |
| Dec 31, 2024 | 503,000.00 |
| Sep 30, 2024 | -2.54 Mn |
| Jun 30, 2024 | 50.71 Mn |
| Mar 31, 2024 | -23.10 Mn |
| Dec 31, 2023 | 39.99 Mn |
| Sep 30, 2023 | -15.81 Mn |
| Jun 30, 2023 | -19.74 Mn |
| Mar 31, 2023 | -28.11 Mn |
| Dec 31, 2022 | -778,000.00 |
| Sep 30, 2022 | -22.51 Mn |
| Jun 30, 2022 | -25.74 Mn |
| Mar 31, 2022 | -35.99 Mn |
| Dec 31, 2021 | -20.79 Mn |
| Sep 30, 2021 | 1.47 Mn |